MetaCap

Cartesian Therapeutics Inc. (RNAC)

NASDAQ: RNACHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.14+0.25 (+4.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RNAC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$187.29M
EPS (TTM)
-$4.78
52-week range
5.60 – 11.00
Day range
5.89 – 6.32
Volume / Avg
279.31K / 139.65K
Beta
—

52-week range

$5.60$11.00

RNAC stock today

Cartesian Therapeutics (RNAC) closed at $6.14 on Nov 20, up 4.24% (+$0.25), versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 279.31K shares, a sign of unusually heavy trading. At this level, RNAC sits near the bottom of its 52-week range of $5.60 to $11.00: 44.2% below the high, set on Jun 24, 2026 and 9.6% above the low.

RNAC is down 14.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.2%. Cartesian Therapeutics has posted a net loss over the last twelve months (EPS of -$4.78), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cartesian Therapeutics

Company profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Carsten Brunn Ph.D.
Headquarters
Frederick, MD
Employees
75
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Cartesian Therapeutics generated $2.8 million in revenue, down 92.8% from fiscal 2024, its first annual decline since 2023. Cartesian Therapeutics reported a net loss of $130.3 million, compared with a loss of $77.4 million a year earlier. Operating margin was -5127.1%.

Cartesian Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.80M$38.91M$26.00M$110.78M$85.08M
Growth-92.81%+49.64%-76.53%+30.21%+412.60%
Net income$-130.30M$-77.42M$-219.71M$35.38M$-25.69M
EPS (diluted)$-5.02$-4.49$-49.76$0.10$-0.22

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$33.67+448.37%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $44.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.38 vs $-1.02
Surprise
+62.75%

RNAC news

All RNAC news

Cartesian Therapeutics peers

Health Care sector
RNAC peer companies
CompanyPrice% ChgMarket capCompare
ANTXAN2 Therapeutics Inc.5.08-2.68%$192.75Mvs RNAC
WHWKWhitehawk Therapeutics Inc.3.07-1.60%$181.16Mvs RNAC
ACIUAC Immune SA1.95-8.45%$193.88Mvs RNAC
SLGLSol-Gel Technologies Ltd.55.17+2.02%$180.63Mvs RNAC
ADCTADC Therapeutics SA1.28-1.54%$180.05Mvs RNAC
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs RNAC
BIOABioAge Labs Inc.4.28-9.13%$196.67Mvs RNAC
NATRNature's Sunshine Products Inc.10.18+0.10%$176.41Mvs RNAC

Indexes, lists and sector

Cartesian Therapeutics stock FAQ

What is Cartesian Therapeutics's stock price today?

RNAC last traded at $6.14 as of Nov 20, 4:00 PM EST, up 4.24% on the day. Prices are delayed at least 15 minutes.

Does Cartesian Therapeutics pay a dividend?

No. Cartesian Therapeutics does not currently pay a regular cash dividend.

Who is Cartesian Therapeutics's CEO?

Dr. Carsten Brunn Ph.D. is the chief executive officer of Cartesian Therapeutics Inc., which has about 75 employees.

Has RNAC ever split its stock?

Yes. The most recent RNAC stock split was a 1-for-30 split on Apr 5, 2024.

What is the RNAC 52-week high?

The 52-week high for RNAC is $11.00 and the 52-week low is $5.60. The stock is currently 44.2% below its high.

Compare RNAC